QSAM Biosciences Buchwert je Aktie
Was ist das Buchwert je Aktie von QSAM Biosciences?
Buchwert je Aktie von QSAM Biosciences, Inc. ist -0.01
Was ist die Definition von Buchwert je Aktie?
Der Buchwert pro Aktie ist das Vermögen eines Unternehmens abzüglich der Verbindlichkeiten geteilt durch die Anzahl der ausstehenden Aktien.
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Buchwert je Aktie von Unternehmen in Health Care Sektor auf OTC im Vergleich zu QSAM Biosciences
Was macht QSAM Biosciences?
QSAM Biosciences, Inc., a clinical stage biotechnology company, develops drugs for the treatment of bone cancer. The company is involved in the development of CycloSam (Samaium-153 DOTMP), a clinical-stage novel radiopharmaceutical for the treatment of bone cancer and related diseases. It has a license agreement with IGL Pharma, Inc. The company was formerly known as Q2Earth, Inc. and changed its name to QSAM Biosciences, Inc. in September 2020. QSAM Biosciences, Inc. was founded in 2004 and is based in Austin, Texas.
Unternehmen mit buchwert je aktie ähnlich QSAM Biosciences
- Backstageplay hat Buchwert je Aktie von -0.01
- Resources of Australia Ltd hat Buchwert je Aktie von -0.01
- Dragontail Systems hat Buchwert je Aktie von -0.01
- Paleo Resources hat Buchwert je Aktie von -0.01
- Ezagoo hat Buchwert je Aktie von -0.01
- Monarca Minerals hat Buchwert je Aktie von -0.01
- QSAM Biosciences hat Buchwert je Aktie von -0.01
- Newtopia hat Buchwert je Aktie von -0.01
- Oceanic Wind hat Buchwert je Aktie von -0.01
- 22nd Century Inc hat Buchwert je Aktie von -0.01
- Blockchain Industries hat Buchwert je Aktie von -0.01
- Pareteum Corp hat Buchwert je Aktie von -0.01
- Pareteum Corp hat Buchwert je Aktie von -0.01